CLNN oral nanotherapeutic for ALS nears NDA submission
CLNN is advancing an oral nanotherapeutic for ALS, citing consistent neurofilament reduction and survival benefits in trials. The company says an NDA submission is imminent, with a confirmatory Phase III and targeted commercialization planned.